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Polymorphisms in TMEM18 are associated with obesity in children and adults. We have reported previously that 
TMEM18 is a regulator of human adipogenesis in vitro [1]. The aim of this study was to investigate the role of 
TMEM18 during adipose tissue (AT) accumulation in vivo. For this, we used the zebrafish as an in vivo model for 
AT development. In addition, we analysed TMEM18 expression in whole AT samples, isolated adipocytes and 
cells of the stroma-vascular fraction (SVF) from lean and obese children of our Leipzig Childhood AT cohort [2], 
and addressed associations with PPARG expression and obesity-related parameters. 
Using whole mount in situ hybridisation on 9 day old zebrafish larvae, we showed co-expression of tmem18 and 
pparg in a visceral region where also first adipocytes are detectable by Nile red staining. Morpholino-mediated 
inhibition of tmem18 expression resulted in a reduction in the number of visceral adipocytes but did not affect 
zebrafish development per se. There was no effect of tmem18 knockdown on eating behaviour suggesting that the 
inhibition of adipocyte formation was not mediated by a central effect. Tmem18-mediated inhibition of 
adipogenesis was accompanied by a significant down-regulation in pparg expression. Using luciferase reporter 
assays in 3T3-L1 cells, we detected a significant activation of the PPARG promoter in presence of Tmem18 
indicating that Tmem18 is an upstream regulator of PPARG signalling. In line with these data, TMEM18 
expression correlated with PPARG expression in whole AT and isolated adipocytes but not in SVF cells of children 
included in our Leipzig AT cohort. Similar to PPARG, TMEM18 expression was down-regulated in adipocytes of 
obese children compared to lean children and correlated with adipocyte diameter, macrophage infiltration, serum 
adiponectin levels and HOMA-IR as a measure of insulin resistance. 
Our findings may indicate a potential role of TMEM18 as a regulator of PPARG signaling during adipogenesis in 
vivo. 
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